Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Macrolide and Nonmacrolide Resistance After 36 Months of Mass Azithromycin Distribution in Burkina Faso: A Cluster
Catherine E Oldenburg1,2,3,4, Boubacar Coulibaly5, Ali Sié1,4,5
1Francis I Proctor Foundation, University of California, SanFrancisco, CA, USA.
Insights
Biannual mass azithromycin distribution to young children did not increase antimicrobial resistance (AMR) genetic determinants in Burkina Faso. This study monitored AMR in children receiving azithromycin versus placebo over 36 months.
Area of Science:
- Global health
- Infectious disease epidemiology
- Antimicrobial stewardship
Background:
- Biannual mass azithromycin distribution reduces child mortality but may drive antimicrobial resistance (AMR).
- The World Health Organization (WHO) recommends AMR surveillance during mass drug administration programs.
- This study investigated the impact of azithromycin distribution on gut AMR in children in Burkina Faso.
Purpose of the Study:
- To evaluate the effect of twice-yearly azithromycin distribution on AMR in children.
- To compare macrolide and non-macrolide resistance determinants between azithromycin and placebo groups.
Main Methods:
- A 1:1 cluster randomized placebo-controlled trial (Community Health with Azithromycin Trial - CHAT) in Burkina Faso (2019-2023).
- Communities received azithromycin or placebo twice yearly.
- Rectal swabs from children were analyzed for AMR genetic determinants using next-generation DNA sequencing at 36 months.
Main Results:
- Analysis of 483 samples from 41 communities at 36 months.
- No statistically significant difference in macrolide resistance determinants between azithromycin and placebo groups (fold-change 1.21, P=0.62).
- No significant difference observed in non-macrolide resistance genes, including beta-lactam resistance (fold-change 1.05, P=0.81).
Conclusions:
- Twice-yearly azithromycin distribution in this Burkina Faso setting did not result in statistically significant increases in macrolide or non-macrolide genetic resistance determinants at 36 months.
- Findings contribute to understanding AMR surveillance in mass drug administration programs.
Background:
Biannual mass azithromycin distribution to children aged 1-59 months reduces all-cause child mortality but selects for antimicrobial resistance (AMR). The World Health Organization (WHO) recommends ongoing surveillance of AMR in the context of azithromycin distribution. We evaluated the impact of twice-yearly distribution of azithromycin compared to placebo on AMR in the gut of children in Burkina Faso.
Methods:
The Community Health with Azithromycin Trial (CHAT) was a 1:1 cluster randomized placebo-controlled trial in Nouna District, Burkina Faso, from 2019 to 2023. Communities were randomized in a 1:1 fashion to twice-yearly azithromycin (20 mg/kg) or matching placebo. At 36 months, rectal swabs were collected from a random sample of 15 children per community in 48 communities participating in the trial and assessed for AMR genetic resistance determinants using next-generation DNA sequencing (DNA-seq). We assessed the fold-change in macrolide and nonmacrolide resistance determinants between treatment groups after 36 months.
Results:
A total of 483 samples from 41 communities were analyzed at 36 months. There was no evidence of a difference in macrolide resistance determinants in the azithromycin group compared to the placebo group (fold-change, 1.21; 95% confidence interval [CI], .96-1.52; P = .62). There was no evidence of a difference in nonmacrolide resistance genes; for example, beta-lactam resistance was similar between treatment groups (fold-change, 1.05; 95% CI, .79-1.40; P = .81).
Conclusions:
In this setting in Burkina Faso, twice-yearly azithromycin distributions to children aged 1-59 months did not lead to statistically significant differences in macrolide or nonmacrolide genetic resistance determinants at 36 months.
Clinical Trial Registration:
ClinicalTrials.gov NCT03676764.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Random Error
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...
Randomized Experiments
Simple randomization
Simple...

